Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Evaluation of lamotrigine in Epilepsy
2015-004901-18Phase 3
- Sponsor
- GSK
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of lamotrigine in epilepsy, sponsored by GSK. Primary endpoint: Incidence of rash in first 8 weeks with valproic acid.
02
Drugs
lamotrigine
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2015-004901-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004901-18.